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Abstract 
Purpose: To prepare punicalagin-loaded nanoliposome and compare its anti-telomerase activity in 
K562 cell line with that of free punicalagin. 
Methods: Punicalagin-loaded nanoliposomes were prepared by extrusion method, and the efficiency of 
punicalagin entrapment was determined by high-performance liquid chromatography (HPLC) method. 
The anti-proliferation effect of the punicalagin in the free and nanoliposomal forms at various doses (0 - 
100 µg/mL) and times (0 - 72 h) on K562 cell line was investigated using 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide ((MTT) assay. Changes in telomerase activity, following treatment with 
punicalagin, of the free and nanoliposomal forms were measured by telomeric repeat amplification 
protocol-enzyme-linked immunosorbent assay.  
Results: The entrapment efficiency of punicalagin was 86.7 ± 1 %. Treatment of K562 cells with 
punicalagin, particularly in the nanoliposomal form, resulted in significant induction of apoptosis and 
inhibition of cell growth. Furthermore, the telomerase activity of the nanoliposomal punicalagin-treated 
cells was significantly inhibited in a time- and dose-dependent manner.  
Conclusion: Punicalagin shows a novel mechanism of anti-telomerase activity, particularly in the 
nanoliposomal form, and may provide a basis for the future development of anti-cancer therapy. 
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Telomerase is a reverse transcriptase enzyme 
responsible for the renewal of chromosomal 
ends, the so-called telomeres [1]. Increase in 
telomerase activity is closely related to 
expression of subunit human telomerase reverse 
transcriptase (hTERT) which is widely expressed 
in almost all tumor-derived human cell lines, and 
present in at least 85 % of human tumor samples 
[2]. Previous studies have showed that 
expression of hTERT and activation of 
telomerase is a crucial step in tumorigenesis [3]. 
It has been reported that inhibition of telomerase 
triggers apoptotic cell death in various cancer cell 
types [4]. 
 
In cancer therapy research, many different 
synthetic chemical agents have been proposed 
for telomerase inhibition but most of these 
compounds have severe toxic side effects on 
normal cells [5]. As a result, extensive studies 
have been carried out in search of compounds 
that are capable of inhibiting telomerase activity 
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and retarding growth of cancer cells without 
affecting normal cells [6,7]. Many studies have 
shown that certain plant-derived compounds 
have this property and were able to inhibit 
telomerase activity in several cancer cell lines 
without affecting normal cells [8,9]. 
 
Punicalagin (Figure 1) a phenolic compound is 
found in some plants such as Punica granatum, 
Terminalia catappa and Combretum molle [10]. It 
has inhibitory effect on different kinds of cancer 
cells including prostate and colon cancer cells 
[11,12]. However, the in vivo instability of 
punicalagin has restricted its use in biomedical 
research [13]. Previous studies showed that 
encapsulation of plant-derived materials in 
nanocarriers such as nanoliposomes markedly 
reduced their in vivo instability and increased 
their effectiveness [14,15]. 
 
A liposome is a colloidal and spherical vesicle 
that can be used as a vehicle for the 
administration of pharmaceutical drugs and 
nutrients [16]. Liposomes have diameter ranging 
from a few nanometers to several micrometers, 
and compose of natural phospholipids and other 
lipids, such as cholesterol [14,15]. To date, the 
anti-proliferative and anti-telomerase activities of 
punicalagin in the free and nanoliposomal forms 
against human K562 cell line have not yet been 
studied. The aim of the present study was to 
prepare punicalagin-loaded nanoliposomes and 
investigate their in vitro antiproliferative and anti-
telomerase activities against human leukemia 











Fetal bovine serum (FBS), RPMI-1640, trypan 
blue, streptomycin and penicillin were purchased 
from Gibco BRL (Gaithersburg, MD, USA). 
Punicalagin (purity ≥ 98 %), soy lecithin, 
cholesterol and Hoechst 33342 were purchased 
from Sigma (St. Louis, MO, USA). TeloTAGGG 
telomerase polymerase chain reaction (PCR)-
enzyme-linked immunosorbent assay (ELISA) 
Plus kit and Annexin V-propidium iodide (PI) 
apoptosis Detection Kit were obtained from 
Roche (Applied Science, Germany). Acetic acid 
and mwere purchased from Merck (Darmstadt, 
Germany). 
 
Preparation of punicalagin-loaded nanoli-
posomes 
 
Punicalagin-loaded nanoliposomes were 
prepared by extrusion method, as described 
previously with some modifications [16]. Briefly, 
soy lecithin and cholesterol (5:1 molar ratio) were 
dissolved in chloroform and then dried to a lipid 
film with a rotary evaporator (Brinkman) at 30 °C 
under controlled vacuum. The dried lipids were 
dispersed by agitation in 1 mL of punicalagin 
solution (100 μg/mL) and sonicated at 4 °C in 
ultrasonic bath (Braun-sonic 2000).  
 
Thereafter, punicalagin-loaded nanoliposomes 
were obtained by extruding of nanoliposomal 
suspension 10 times through a polycarbonate 
membrane filter with 100 nm pores. Excess free 
punicalagin and larger lipid aggregation were 
separated by ultracentrifugation (100,000 g, 30 
min). The control nanoliposomes were prepared 
similarly, but PBS (pH 7.4) was used instead of 
the punicalagin solution.  
 
Characterization of nanoliposomes 
 
Punicalagin content of the nanoliposomes was 
determined by HPLC method [17] following 
dissolution in 0.1 % Triton X-100. After 
dissolution, 20 µL of lysate was injected into the 
HPLC column (C18, 4.5 × 150 mm, 5 µm, 
Phenomenex, Torrance, USA). The diode array 
UV detector and the mobile phases, including 
water (A); 88 % water + 12 % methanol (B); 20 
% water + 80 % methanol (C); methanol (D) was 
used. The elution started with 100 % A (5 min) 
and a gradient was used to obtain 100 % B at 10 
min, holding it isocratic for 3 more minutes and 
from 13 to 35 min. Subsequently, a linear 
gradient was used to obtain 50 % B and 50 % C, 
and then 100 % C at 40 min and the column was 
washed with 100 % D at 42 min. The flow rate 
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was 0.9 mL/min. Finally, the loading (L) of 
punicalagin was calculated as in Eq 1.  
 
L (%) = {(WnV)/(VWi)}100 ………………. (1) 
 
where Wn is the amount of punicalagin in 
nanoliposomes, V the total sample volume tested 
and Wi the initial amount of punicalagin used in 
preparing the nanoliposomal formulation. The 
polydispersity index, size distribution, zeta 
potential and mean particle size of the 
nanoliposomes was evaluated using a Malvern 
zetasizer (Malvern Instrument, Worcestershire, 
UK) apparatus, as reported previously [8]. The 
analysis of the size and shape of the punicalagin-
loaded nanoliposomes were carried out by cryo-




The human chronic myelogenic leukemia cell line 
K562 was purchased from Pasteur Institute of 
Iran (Tehran, Iran). The K562 cells were 
maintained in RPMI-1640 medium supplemented 
with 10 % FBS along with streptomycin (100 
µg/ml) and penicillin (100 units/ml) and were 
grown in a humidified incubator (37 ºC and 5 % 
CO2). Punicalagin was dissolved in the deionized 
water to obtain a 100 µg/ml stock solution and all 
subsequent dilutions were made in RPMI 
medium. 
 
Cell proliferation assay 
 
Cell proliferation was determined using the 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) assay as previously 
described [19]. In brief, 5 × 103 cells were 
incubated in 96 well plates in the presence of 
different concentrations of punicalagin in the 
nanoliposomal and free forms (0, 10, 50 and 100 
µg/mL) for 24, 48, and 72 h in a final volume of 
200 µl. At the end of the treatment, 20 µL of MTT 
(5 mg/mL in PBS) was added to each well and 
then incubated at 37 °C for an additional 2 h. The 
resultant precipitate was dissolved in 200 µL of 
DMSO and the viability of cells was assessed by 
measuring the optical density at 570 nm. Three 
replicates were done for each concentration of 
punicalagin in the free and nanoliposomal forms. 
 
Nuclear staining with Hoechst 33342 
 
K562 cells were incubated with punicalagin in the 
free and nanoliposomal forms (0, 10, 50 and 100 
µg/mL) for 72 h and washed with PBS buffer. 
After fixation in freshly prepared ice-cold 
paraformaldehyde (0.1 %) for 10 min, the cells 
were stained with Hoechst 33342 (50 µg/mL) for 
1 min in the dark and morphologic changes were 
observed under the fluorescent microscope. 
Thereafter, the percentage of apoptotic cells was 
assessed after counting at least 100 cells per 
treatment group.  
 
Flow cytometric analysis 
 
The K562 cells were treated with varying 
concentrations of the punicalagin and its 
nanoliposomal form (0, 10, 50 and 100 µg/mL) 
for 72 h. At the end of each treatment, the cells 
were collected and quantitative apoptotic death 
assay was done by Annexin V and PI staining 
following the manufacturer’s protocol. Apoptotic 
cells were measured immediately by flow 
cytometry. 
 
Telomerase activity assay 
 
The K562 cells were first treated with different 
concentrations (0, 10, 50 and 100 µg/mL) of the 
punicalagin in the encapsulated and free forms 
for 72 h. Moreover, in order to investigate the 
effect of different incubation times on telomerase 
activity, punicalagin in the free and encapsulated 
forms at 100 µg/mL was incubated for different 
time intervals (0, 24, 48 and 72 h). At the end of 
each treatment, the cells were harvested and 
washed twice with washing buffer and lysed in 
the lysate buffer. The protein concentration was 
determined using Bradford method [20]. The 
telomerase activity was assessed using 
TeloTAGGG telomerase PCR-ELISA plus 
Detection Kit according to the manufacturer’s 
protocol (Roche Applied Science, Germany). In 
the presence of biotin-labeled primers cell 
extracts were incubated for 30 min and the 
telomeric repeats were built by cell-extracted 
telomerase.  
 
Thereafter, the elongated products as well as a 
special internal standard were amplified by PCR. 
The PCR products were denatured and split in 
two aliquots which were separately hybridized to 
digoxigenin-labeled detection specific probes and 
allowed to bind to a streptavidin coated, 96-well 
plate. Then the biotin-labeled PCR products were 
detected using peroxidase-conjugated antibody. 
Absorbance of the developed blue color was 
measured at 450 nm by STAT-FAX 3200 ELISA 
reader (Awareness Technology, Inc., USA). As 
the negative control, each extract was heated for 
10 min at 95 °C prior to the PCR step. 
Thereafter, relative telomerase activity (RTA) of 
each sample was determined according to the 
instruction of TeloTAGGG Telomerase PCR-
ELISA PLUS kit. 
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The results are presented as mean ± standard 
deviation (SD). Analysis of variance was done to 
determine significant level among the test groups 
and differences with p < 0.05 were considered 
statistically significant. Data were analyzed using 





The data revealed that percentage of punicalagin 
entrapment efficiency was 86.7 ± 1 %. Table 1 
shows the mean particle size, zeta-potential, and 
polydispersity index of empty and punicalagin-
loaded nanoliposomes. The size homogeneity of 
empty and loaded nanoliposomes suggested that 
punicalagin was entrapped into nanoliposomes, 
according to previous reports [14-16]. In addition, 
zeta-potential and polydispersity index of the 
punicalagin-loaded nanoliposomes showed that 
nanoliposomes have appropriate stability in the 
aqueous dispersion [14]. 
 
The viability of the K562 cells after treatment with 
punicalagin in the free and encapsulated forms 
was examined by MTT assay. The results 
revealed that the cell proliferation was inhibited in 
the K562 cells in a time- and dose-dependent 
manner (Figure 2). In all conditions, the 
punicalagin-loaded nanoliposomes were more 
effective than those of free punicalagin on K562 
cell growth. As shown in Figure 2, the extent of 
inhibition increased significantly at 24 h with the 
lowest concentration of punicalagin in the 
encapsulated and free forms which continued to 
rise at 48 and 72 h durations at the maximum 
concentration. 
 
Cryo-TEM analysis revealed that nanoliposomes 
had a fine homogeneity and were spherical in 
shape (Figure 3). Under a fluorescence 
microscope, punicalagin-treated cells stained 
after 72 h showed characteristic apoptotic 
features such as chromatin condensation and 
nuclear fragmentation (Figure 4c and 4d). In 
particular, in the presence of punicalagin-loaded 
nanoliposomes, the percentage of the apoptotic 
cells was increased in a dose-dependent manner 
and percentage of apoptotic cells was also 
higher than in those exposed to free punicalagin 
(Figure 4a). 
 
Flow cytometry results 
 
As shown in the representative FACS analysis 
scatter-grams, cells treated with punicalagin, 
particularly in the encapsulated form at 10, 50 
and 100 µg/mL for 72 h showed strong shift from 
viable cells to the early and late apoptotic cells 
(Figure 5). 
 
When compared to untreated cells, the RTA of 
K562 cells were significantly suppressed in a 
concentration and time-dependent manner after 
treatment with punicalagin, particularly in the 
loaded form (Figures 6 and 7). Compared to 
control group, results showed that RTA of cells 
treated with 100 µg/mL punicalagin in the free 
and nanoliposomal forms at 72 h was reduced to 
22.5 ± 1.5 and 13.1 ± 0.5 %, respectively (Figure 
6). Similarly, as shown in Figure 7, RTA of K562 
cells treated with punicalagin in the free and 
loaded forms was reduced to 28.2 ± 1.2 % and 
17.1% ± 1.8 at 48 h respectively, as compared to 




Punicalagin is an ellagitannin, found in 
Pomegranate (Punica granatum L.) and some 
other plants. [10]. Evidence of the health benefit 
of punicalagin are manifested in its strong 
antioxidative, anti-cancer, anti-inflammatory, and 
anti-atherosclerotic activities [11,12]. Punicalagin 
is a major antioxidant polyphenol in pomegranate 
juice, where it may reach levels of up to 1 g/L of 
juice [21]. It has potential antiviral effect against 
enterovirus 71 and could be used for the therapy 
of various immune pathologies [22]. 
 
Moreover, punicalagin has an inhibitory effect on 
some cancer cells, including HT-29 and HCT116 
colon cancer cells [23]. It was reported that 
telomerase activity was an important marker for 
tumorigenesis and inhibition of this enzyme could 
be used for the development of anti-proliferative 
agents and anti-tumor drugs [1-4]. 
 
Table 1: Particle size, zeta-potential and polydispersity index of the empty and punicalagin-loaded 
nanoliposomes 
 






Empty nanoliposomes 91.7±0.15 −1.03±0.08 0.16±0.04 
Punicalagin-loaded 
nanoliposomes 
95.7±0.15 −1.24±0.13 0.16±0.05 
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Figure 3: Dose- and time-dependent inhibition of K562 cell growth by punicalagin in the free (a) and 
nanoliposomal (b) forms. Data are expressed as mean ± standard deviation from three independent experiments 
(*p < 0.05 and **p < 0.001) 
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Figure 4: Extent of apoptosis in K562 cells after treatment with punicalagin in the free and nanoliposomal forms 
(a). Compared to control cells (b), fragmented or condensed nuclei indicative of apoptosis could be observed in 
the punicalagin-treated cells with free (c) and nanoliposomal forms (d), as arrows indicate. Data represent mean 
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Figure 5: Representative FACS analysis of treated cells with 10, 50 and 100 µg/mL of punicalagin in the free (a), 
and loaded (b) forms after staining with Annexin V/PI. Lower Left (LL): AnnexinV- PI-, Lower Right (LR): Annexin 
V +PI-, Upper Right (UR): Annexin V+PI+, Upper Left (UL): Annexin V- PI+ 
 
Plant-derived compounds that can suppress 
telomerase activity might be potential candidates 
for cancer therapy because telomerase activity is 
found in a wide variety of cancer cells, including 
leukemia; this phenomenon could enhance 
resistance to apoptosis through multiple 
mechanisms [8,9,15]. 
However, the main problem associated with the 
application of some plant-derived compounds is 
biological instability [13]. Previous studies 
showed that the incorporation of plant-derived 
compounds into nanoliposomes could overcome 
this limitation [14]. It has been reported that 
encapsulation of plant-derived materials in nano- 
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Figure 6: Concentration-dependent inhibition of relative telomerase activity by punicalagin in the free and loaded 




Figure 7: Time-dependent inhibition of relative telomerase activity by punicalagin in the free and encapsulated 
forms (100 μg/mL) as detected by telomeric repeat amplification protocol enzyme-linked immunosorbent assay 
(*p < 0.05) 
 
liposomes can increase their stability and 
effectiveness [24]. 
 
In this study we found that punicalagin, in 
particular in the loaded form, significantly 
inhibited proliferation and telomerase activity in 
K562 cells in a concentration as well as time 
dependent manner. The data also indicated that 
anti-telomerase activity of punicalagin-loaded 
nanoliposomes in K562 cells was higher than 
those of free punicalagin.  
 
Several hypotheses, including increased 
penetration of plant-derived compounds into cells 
and stability of encapsulated materials may 
explain the mechanism of enhanced anticancer 
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efficacies of this nanoliposomal formulation [25-
30]. Our data showed a significant and positive 
correlation between telomerase inhibition and 
induction of apoptosis.  
 
Similar anticancer activity had been reported in 
previous investigations with other liposomal 
natural plant products such as celastrol [25], 
epigallocatechin-3-gallate [24], gossypol [26], 
wagonin [27], berberin [28], curcumin [29] and 
tea polyphenol [30] in various cancer cell lines. 
Therefore, punicalagin and other effective plant-
derived agents in the free and encapsulated 
forms may be considered as promising strategy 




Nanoliposomal punicalagin with acceptable 
characteristics has been successfully prepared. 
The findings of this study demonstrate that 
punicalagin, in the nanoliposomal form has 
potent anti-telomerase effect on K562 cells, and 
also time- and concentration-dependently inhibits 
cell growth in this cell line. Therefore, the 
developed nanoliposomal formulation may 
provide a basis for the future development of 
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